Don't forget to nominate 2020's fiercest women in life sciences

Three people looking at a display of black and white photos depecting a diverse group of people
(Gerd Altmann)

There’s still time to send us your nominations for this year’s Fiercest Women in Life Sciences! Submissions close next week.

To recap, we’re looking for women in biotech, pharma and medtech who, in spite of challenges both unique to the industry and to being female, stand out as leaders, innovators and mentors. They can be industry professionals, academics, regulators, venture capitalists—you name it.

We are often asked whether we have a list of criteria for consideration. We don’t. If a particular woman is making a mark on the life sciences industry, we want to hear about her.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

For a taste of what we’re looking for, check out last year's feature here, 2018’s here and 2017’s here. Please submit your nominations using the form below, including details about your nominee to help us understand her contributions to the field. The form will be open until 11:59 p.m. EDT on Monday, Aug. 17. 

 

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.